Engineered immune cells take aim at stubborn leukemia
NCT ID NCT06871410
First seen Jun 25, 2026 · Last updated Aug 04, 2026 · Updated 5 times
Summary
This early-phase trial is testing a new cell therapy called CD83 CAR T cells in 26 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy uses a patient's own immune cells, genetically modified to recognize and attack a protein (CD83) found on leukemia cells. The main goal is to find a safe dose and check for side effects, while also seeing if the treatment can shrink the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD83 CAR T cells (a genetically engineered immune cell therapy)
- What this could lead to
- If it works, this could offer a new treatment option for patients with hard-to-treat AML, potentially reducing the risk of relapse after stem-cell transplant.
- What could go wrong
- This is a very early phase I trial with only 26 participants, so safety and dosing are still being figured out. The therapy may not work, and there are risks like cytokine release syndrome or other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to wake up immune system against Hard-to-Treat leukemia
- New drug combo aims to outsmart resistant leukemia
- Gentler chemo approach shows promise for tough blood cancers in older patients
- Selective immune cell removal may tame transplant complications
- Promising combo for IDH1 leukemia hits early snag – trial stopped
- Engineered immune cells take aim at Hard-to-Treat leukemia